Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential... Read more.
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa (HS), reinforcing efficacy and safety profile of ruxolitinib cream Results... Read more.
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31 One-year data from an interim analysis... Read more.
Illumination and Nintendo Announce New Animated Film Based on the World of Super Mario Bros.
SANTA MONICA, Calif. & KYOTO, Japan–(BUSINESS WIRE)–Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co.,... Read more.
LEO Pharma Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial at the 2024 AAD Annual Meeting
Continuing the momentum for LEO Pharma at the ongoing American Academy of Dermatology (AAD) Annual Meeting, a late-breaker presentation shared positive results from... Read more.
MBLY Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Mobileye Global Inc. (MBLY) Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
RADNOR, Pa.–(BUSINESS WIRE)–#classaction–The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities... Read more.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 8, 2024, the Compensation Committee of Mirum’s... Read more.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 8, 2024, the Compensation Committee of Mirum’s... Read more.
Kirby McInerney LLP Reminds Innodata, Inc. Investors of Class Action Filing and Encourages Investors to Contact the Firm
NEW YORK–(BUSINESS WIRE)–$INOD #Investigation–The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed... Read more.
DADA NEXUS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Dada Nexus Limited – DADA
NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti,... Read more.